Psilocybin, the Third Eye Microdose compound in magic mushrooms, has been hailed by many users as an alternative to pharmaceuticals. While research is growing with promising results, it’s not yet clear if mushroom microdose can truly treat mental health issues. CBC’s Nick Purdon visits two Canadian stores that sell the mushrooms used for microdoses and speaks to people who swear by it and researchers trying to understand if it works.
People who microdose say they use a variety of methods to get the drug, but it’s typically a dried mushroom with psilocin in it. The psilocin is the active ingredient that produces psychoactive effects, and different strains of the mushroom can have varied potency. That’s why it’s important for people who are starting out with microdosing to start with very small amounts of the substance and gradually increase the dosage.
Exploring Balance: The Art and Science of Mushroom Microdosing
The psilocybin that is in these mushrooms is a Schedule 1 drug. It means that it has a high potential for abuse and no current accepted medically therapeutic use. It’s also a controlled substance and illegal to produce, sell or possess without special permits.
The psychedelics industry has been growing with a new generation of entrepreneurs trying to find ways to commercialize the drugs. However, it is important to note that there is no scientific evidence of any long-term benefits or risks associated with taking psilocybin at these microdose levels. It’s also recommended that anyone interested in trying this method seek the advice of a qualified addiction and mental health professional before doing so.